Federal Register of Legislation - Australian Government

Primary content

PB 23 of 2021 Other as made
This instrument amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015) to add, delete and alter listed pharmaceutical items and associated periods and circumstances.
Administered by: Health
Registered 31 Mar 2021

PB 23 of 2021

 

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021
(No. 3)

 

National Health Act 1953

___________________________________________________________________________

 

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

 

Dated         31 March 2021

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

THEA CONNOLLY

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health


 

___________________________________________________________________________

1          Name of Instrument

(1)          This Instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2021 (No. 3).

(2)          This Instrument may also be cited as PB 23 of 2021.

2          Commencement

This Instrument commences on 1 April 2021.

3          Amendment of National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

Schedule 1 amends the National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015).

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

                             

                             


Schedule 1       Amendments

[1]             Schedule 1, after entry for Indacaterol with glycopyrronium

insert:

Indacaterol with glycopyrronium and mometasone

Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler)

20

30

5

 

Indacaterol with glycopyrronium and mometasone

Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler)

20

30

5

 

[2]             Schedule 1, after entry for Rivastigmine in the form Transdermal patch 27 mg

insert:

Romosozumab

Injection 105 mg in 1.17 mL single use pre-filled syringe

20

2

5

 

[3]             Schedule 1, after entry for Sertraline in the form Tablet 50 mg (as hydrochloride)

insert:

 

Tablet 50 mg (as hydrochloride) (USP)

20

30

5

 

[4]             Schedule 1, after entry for Sertraline in the form Tablet 100 mg (as hydrochloride)

insert:

 

Tablet 100 mg (as hydrochloride) (USP)

20

30

5